SELLAS Life Sciences (SLS) Return on Invested Capital (2013 - 2017)
SELLAS Life Sciences (SLS) reported Return on Invested Capital of 0.01% for Q4 2017, down 525.11% on a QoQ basis from 0.0% in Q3 2017.
SELLAS Life Sciences (SLS) has 3 years of Return on Invested Capital data on file, last reported at 0.01% in Q4 2017.
- Quarterly Return on Invested Capital changed N/A year-over-year to 0.01% in Q4 2017, while the trailing twelve-month figure through Dec 2017 was 0.01% (changed N/A YoY) and the FY2021 annual result came in at 0.01%, changed 0.0% from the prior year.
- Return on Invested Capital eased to 0.01% in Q4 2017 per SLS's latest filing, from 0.0% in the prior quarter.
- Across five years, Return on Invested Capital topped out at 0.0% in Q3 2017 and bottomed at 0.01% in Q3 2014.
- The 3-year median for Return on Invested Capital is 0.01% (2014), against an average of 0.01%.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -0.01% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 0.00% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -0.01% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 0.00% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 0.01% |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | -0.01% |
| Sep 30, 2017 | 0.00% |
| Jun 30, 2017 | 0.00% |
| Sep 30, 2014 | -0.01% |
| Jun 30, 2014 | -0.01% |
| Mar 31, 2014 | -0.01% |
| Dec 31, 2013 | -0.01% |